Stock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates

Stock Track

2025/11/05

MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.

The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.

Beyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1188878776"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188878776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188878776?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188878776","market":"nz","top_or_hot":-1,"title":"Stock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates","media":"Stock Track","content":"<p>MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.</p>\n\n<p>The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.</p>\n\n<p>Beyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-11-05 21:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.</p>\n\n<p>The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.</p>\n\n<p>Beyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凱德生物醫療","start_time":0,"source_url":"","article_id":"1188878776","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188878776","pubTimestamp":1762348127,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"个股追踪|MannKind盘前飙升5.84%，第三季度业绩强劲，每股收益和营收超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.\nThe company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.\nBeyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}